

COVID-19 Pneumonia

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT04409262 2020-002275-34
WA42511

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04409262 2020-002275-34 WA42511
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥12 Years

Healthy Volunteers
No
